1. Home
  2. BWAY vs ALLO Comparison

BWAY vs ALLO Comparison

Compare BWAY & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BWAY
  • ALLO
  • Stock Information
  • Founded
  • BWAY 2003
  • ALLO 2017
  • Country
  • BWAY Israel
  • ALLO United States
  • Employees
  • BWAY N/A
  • ALLO N/A
  • Industry
  • BWAY Medical/Dental Instruments
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • BWAY Health Care
  • ALLO Health Care
  • Exchange
  • BWAY Nasdaq
  • ALLO Nasdaq
  • Market Cap
  • BWAY 280.7M
  • ALLO 252.9M
  • IPO Year
  • BWAY 2019
  • ALLO 2018
  • Fundamental
  • Price
  • BWAY $14.97
  • ALLO $1.33
  • Analyst Decision
  • BWAY Strong Buy
  • ALLO Buy
  • Analyst Count
  • BWAY 2
  • ALLO 12
  • Target Price
  • BWAY $18.00
  • ALLO $8.80
  • AVG Volume (30 Days)
  • BWAY 61.1K
  • ALLO 2.9M
  • Earning Date
  • BWAY 11-11-2025
  • ALLO 11-06-2025
  • Dividend Yield
  • BWAY N/A
  • ALLO N/A
  • EPS Growth
  • BWAY 679.98
  • ALLO N/A
  • EPS
  • BWAY 0.11
  • ALLO N/A
  • Revenue
  • BWAY $46,084,000.00
  • ALLO N/A
  • Revenue This Year
  • BWAY $335.63
  • ALLO N/A
  • Revenue Next Year
  • BWAY $22.10
  • ALLO $100.00
  • P/E Ratio
  • BWAY $55.30
  • ALLO N/A
  • Revenue Growth
  • BWAY 26.50
  • ALLO N/A
  • 52 Week Low
  • BWAY $7.84
  • ALLO $0.86
  • 52 Week High
  • BWAY $17.00
  • ALLO $3.78
  • Technical
  • Relative Strength Index (RSI)
  • BWAY 48.22
  • ALLO 59.19
  • Support Level
  • BWAY $14.65
  • ALLO $1.20
  • Resistance Level
  • BWAY $15.60
  • ALLO $1.43
  • Average True Range (ATR)
  • BWAY 0.67
  • ALLO 0.07
  • MACD
  • BWAY -0.11
  • ALLO 0.02
  • Stochastic Oscillator
  • BWAY 29.79
  • ALLO 60.00

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: